Clinical and Pharmacokinetic Risk Factors for High-dose Methotrexate-induced Toxicity in Children with Acute Lymphoblastic Leukemia: A Logistic Regression Analysis
Authors:
- Charlotte RaskCRCharlotte Rask
- Freidoun AlbertioniFAFreidoun Albertioni
- Soeren M. BentzenSBSoeren M. Bentzen
- Henrik SchroederHSHenrik Schroeder
- Curt PetersonCPCurt Peterson
- 1 January 1998
- journal article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 37 (3) , 277-284
Abstract
The clinical and pharmacokinetic risk factors for toxicity after high-dose methotrexate (MTX) in children with acute lymphoblastic leukemia were evaluated using a multivariate statistical analysis. Plasma samples were collected after 44 24-h infusions of MTX (5 or 8 g/m2) in 13 children (age 3.3-12.9 years) and subsequently analyzed by HPLC to determine the MTX and 7-hydroxymethotrexate (7-OHMTX) concentrations. Toxicity was evaluated according to the WHO criteria. Severe toxicity was not observed. Oral mucositis (WHO grade > or = 1) was significantly related to a high plasma MTX concentration at 28 h after starting the infusion (p = 0.013), a low ratio of plasma 7-OHMTX/MTX at 66 h after starting the infusion (p = 0.049), and a slow clearance of MTX (p = 0.048). The risk of leukopenia (WHO grade > or = 2) increased significantly with the number of courses (p = 0.02). Increasing age and a long exposure to a high MTX concentration in plasma (AUC) were significant risk factors (p = 0.047 and p = 0.009, respectively) for developing elevated liver enzymes (ALAT) (WHO grade > or = 2). This study shows how a statistical model can be used to identify clinical and pharmacokinetic factors that may influence MTX-induced toxicity. The therapeutic ratio could thereby potentially be improved.Keywords
This publication has 14 references indexed in Scilit:
- Evaluation of clinical assays for measuring high-dose methotrexate in plasmaClinical Chemistry, 1996
- Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the ratCancer Chemotherapy and Pharmacology, 1994
- Evaluation of Serious Adverse Events in Patients Treated with Protocols Including Methotrexate InfusionsPediatric Hematology and Oncology, 1994
- High‐dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude total therapy study XMedical and Pediatric Oncology, 1988
- Pharmacokinetic parameter estimates from several least squares procedures: Superiority of extended least squaresJournal of Pharmacokinetics and Biopharmaceutics, 1985
- Enzymatic Assay for Methotrexate in ErythrocytesScandinavian Journal of Clinical and Laboratory Investigation, 1985
- Report on Various Clinical Studies on High Dose Methotrexate in Europe (Non-Eortc)Oncology Research and Treatment, 1981
- The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapyCancer Letters, 1980
- Evaluation of overall toxicity of high‐dosage methotrexate regimensMedical and Pediatric Oncology, 1979
- Methotrexate: clinical pharmacology, current status and therapeutic guidelinesCancer Treatment Reviews, 1977